Why should you keep an eye on Corcept Therapeutics Inc (CORT)?

Corcept Therapeutics Inc (NASDAQ: CORT) is -26.26% lower on its value in year-to-date trading and has touched a low of $17.86 and a high of $34.28 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CORT stock was last observed hovering at around $23.01 in the last trading session, with the day’s gains setting it 0.94%.

Currently trading at $23.95, the stock is 5.03% and -7.75% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.4 million and changing 4.09% at the moment leaves the stock -9.28% off its SMA200. CORT registered 3.95% gain for a year compared to 6-month loss of -22.42%. The firm has a 50-day simple moving average (SMA 50) of $4.69 and a 200-day simple moving average (SMA200) of $20.99.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

The stock witnessed a 2.13% gain in the last 1 month and extending the period to 3 months gives it a -3.85%, and is 11.55% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.41% over the week and 4.51% over the month.

Current P/E ratio is 29.59 and Fwd P/E is 26.43. Profit margin for the company is 20.19%. Distance from 52-week low is 34.10% and -30.12% from its 52-week high. The company has generated returns on investments over the last 12 months (19.68%).

Corcept Therapeutics Inc quarterly earnings per share for the current quarter are estimated at $0.26 with sales reaching $129.3M over the same period.The EPS is expected to grow by 5.93% this year, but quarterly earnings will post 18.50% year-over-year. Quarterly sales are estimated to grow 25.50% in year-over-year returns.

Corcept Therapeutics Inc (CORT) Top Institutional Holders

370 institutions hold shares in Corcept Therapeutics Inc (CORT), with institutional investors hold 92.33% of the company’s shares. The shares outstanding are 107.83M, and float is at 87.87M with Short Float at 21.99%. Institutions hold 81.75% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 15.29 million shares valued at $340.18 million. The investor’s holdings represent 14.91% of the CORT Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 9.31 million shares valued at $207.17 million to account for 9.08% of the shares outstanding. The other top investors are Ingalls & Snyder which holds 8.36 million shares representing 8.15% and valued at over $186.02 million, while Renaissance Technologies, LLC holds 6.53% of the shares totaling 6.7 million with a market value of $149.07 million.

Corcept Therapeutics Inc (CORT) Insider Activity

A total of 54 insider transactions have happened at Corcept Therapeutics Inc (CORT) in the last six months, with sales accounting for 24 and purchases happening 30 times. The most recent transaction is an insider sale by Swisher Daniel N JR,the company’sDirector. SEC filings show that Swisher Daniel N JR sold 2,200 shares of the company’s common stock on Feb 01 at a price of $22.00 per share for a total of $48400.0. Following the sale, the insider now owns 0.0 shares.

Corcept Therapeutics Inc disclosed in a document filed with the SEC on Jan 02 that Swisher Daniel N JR (Director) sold a total of 2,200 shares of the company’s common stock. The trade occurred on Jan 02 and was made at $22.11 per share for $48642.0. Following the transaction, the insider now directly holds 0.0 shares of the CORT stock.

Still, SEC filings show that on Dec 22, Guyer William (Chief Development Officer) disposed off 10,000 shares at an average price of $32.00 for $0.32 million. The insider now directly holds 6,643 shares of Corcept Therapeutics Inc (CORT).

Corcept Therapeutics Inc (CORT): Who are the competitors?

The company’s main competitors (and peers) include Eli Lilly & Co. (LLY) that is trading 110.41% up over the past 12 months. Johnson & Johnson (JNJ) that is -3.01% lower over the same period.